KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to -$41.8 million.

  • Evolent Health's Cash from Financing Activities fell 36419.85% to -$41.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.1 million, marking a year-over-year increase of 18471.07%. This contributed to the annual value of -$565000.0 for FY2024, which is 10020.08% down from last year.
  • Evolent Health's Cash from Financing Activities amounted to -$41.8 million in Q3 2025, which was down 36419.85% from -$8.9 million recorded in Q2 2025.
  • Evolent Health's Cash from Financing Activities' 5-year high stood at $379.7 million during Q1 2023, with a 5-year trough of -$103.4 million in Q2 2024.
  • For the 5-year period, Evolent Health's Cash from Financing Activities averaged around $23.2 million, with its median value being -$8.9 million (2025).
  • In the last 5 years, Evolent Health's Cash from Financing Activities skyrocketed by 2690171.61% in 2022 and then tumbled by 67715.13% in 2023.
  • Quarter analysis of 5 years shows Evolent Health's Cash from Financing Activities stood at $60.9 million in 2021, then plummeted by 117.82% to -$10.9 million in 2022, then plummeted by 677.15% to -$84.4 million in 2023, then soared by 214.93% to $96.9 million in 2024, then tumbled by 143.13% to -$41.8 million in 2025.
  • Its Cash from Financing Activities stands at -$41.8 million for Q3 2025, versus -$8.9 million for Q2 2025 and $107.9 million for Q1 2025.